BNTX - Week In Review: Junshi Out-Licenses Ex-China Rights For COVID-19 Therapeutic To Lilly
Coronavirus Pandemic
Junshi Biosciences [HK:1877] out-licensed ex-China rights for a therapeutic antibody aimed at preventing and treating COVID-19 to Eli Lilly (LLY) (see story). JS016 is a recombinant fully human monoclonal neutralizing antibody that is specific to the SARS-CoV-2 surface spike protein receptor binding domain and blocks the binding of viruses to host cell surface receptor ACE2. The antibody research was developed jointly by Junshi and the Institute of Microbiology, Chinese Academy of Sciences. Lilly plans to file an IND and start trials in the US in Q2 of 2020.
Sorrento Therapeutics (SRNE), a